Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
The agency ordered Poseida to halt the trial in August after a patient died but is now allowing the company to resume the study with an amended protocol.
The Prostate Cancer Biomarker Enrichment and Treatment Selection Study will match patients to treatments based on liquid biopsy-based biomarker evaluation.
The drug, LP-184, demonstrated increased efficacy against prostate cancer cells overexpressing PTGR1 in preclinical studies and inspired further research.
Using baseline blood samples, researchers have identified an eight-gene expression signature to predict patient responses to Zytiga plus prednisone or Xtandi.
Trial data, however, raised doubt about Lynparza's benefit in metastatic castration-resistant prostate cancer patients with non-BRCA1/2 HRR gene mutations.
